Redeye: CTEK - More than meets the eye
Redeye updates its estimates following CTEK’s Q4 report, which was largely impacted by General Motors generating one-time sales and write-downs simultaneously. CTEK generated solid underlying organic growth despite tough comps, but profitability was slightly below our estimates due to long-term investments putting a short-term dent in the margins. We are optimistic about 2025 for CTEK and consider the upcoming CMD a potential catalyst in increasing the stock market’s general understanding of the company’s ongoing business.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/